Bio-Techne
TECH
$51.68
+1.65%
Bio-Techne Corp. is a life sciences manufacturer that supplies essential consumables and instruments to the pharmaceutical, biotechnology, academic, and diagnostic markets. The company operates as a specialized provider with a strong market position in protein sciences, which constitutes about 75% of its revenue, leveraging a portfolio of reagents and analytical tools critical for research. The current investor narrative is dominated by concerns over recent financial performance, including a slight year-over-year revenue decline and a sharp stock price correction, raising questions about near-term growth prospects and margin stability in a challenging biotech funding environment.…
TECH
Bio-Techne
$51.68
Investment Opinion: Should I buy TECH Today?
The synthesized recommendation is Hold. The core thesis is that while TECH possesses a strong financial foundation and is deeply oversold, the lack of a visible near-term catalyst for revenue re-acceleration and persistent margin pressure warrants caution, making the stock a 'show me' story rather than a clear buy.
Supporting this Hold rating are several data points: the stock trades at a forward P/E of 23.35x based on a consensus EPS of $2.66, which is not cheap for a company with currently negative revenue growth. The balance sheet is a clear strength, with a current ratio of 3.46 and a debt-to-equity of 0.23. However, profitability metrics are weak, with a Return on Equity of just 3.83% and gross margin trending down. Analyst sentiment is cautiously optimistic (leaning bullish), but the limited coverage (5 analysts) and lack of a provided consensus price target reduce conviction.
The two biggest risks that could invalidate this Hold thesis are: 1) A further deceleration in revenue growth or another quarterly decline, which would crush the forward earnings narrative, and 2) A breakdown below the $43.20 support level, triggering technical selling. This Hold would upgrade to a Buy if revenue returns to positive year-over-year growth and gross margins stabilize above 65%, confirming the turnaround. It would downgrade to a Sell if the forward P/E expands above 30x without corresponding earnings growth or if the 52-week low is decisively broken. Relative to its own challenged fundamentals, the stock appears fairly valued to slightly overvalued, as the market is already pricing in a significant recovery that has yet to begin.
Sign up to view all
TECH 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The investment case is bifurcated: compelling value characteristics (oversold, strong balance sheet) are directly opposed by deteriorating fundamentals (negative growth, margin compression). The neutral stance reflects this stalemate. The forward P/E of 23.35x is the fulcrum; it is neither cheap enough to ignore the risks nor expensive enough to short given the solid cash flow. The stance would upgrade to bullish on concrete evidence of revenue re-acceleration and margin stabilization for two consecutive quarters. It would turn bearish if the stock breaks below $43.20 on high volume, signaling a failure of the current support thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Techne's 12-month outlook, with a consensus price target around $67.18 and implied upside of +30.0% versus the current price.
Average Target
$67.18
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$41 - $67
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is a mid-cap stock with moderate institutional interest. The consensus sentiment, inferred from recent institutional ratings, leans bullish with firms like Citigroup, UBS, and TD Cowen maintaining 'Buy' ratings, though Wells Fargo and Stifel have 'Overweight' and 'Hold' ratings, respectively. The average revenue estimate for the forward period is $1.56 billion, with a range from $1.54 billion to $1.59 billion, and an average EPS estimate of $2.66, but a specific consensus price target is not provided in the data to calculate implied upside or downside. The target range and recent rating actions signal moderate conviction; the lack of downgrades following the stock's steep decline in early 2026 suggests analysts may be viewing the weakness as an overreaction, though the limited number of covering analysts means price discovery can be less efficient and more volatile.
Bulls vs Bears: TECH Investment Factors
The evidence currently tilts bearish, as concrete financial deterioration (negative revenue growth, margin compression) outweighs bullish qualitative factors like a strong balance sheet. The bear case is supported by hard data showing operational weakness, while the bull case relies heavily on anticipated recovery and oversold technicals. The single most important tension in the investment debate is whether the company's strong financial fortress (3.46 current ratio, $223M FCF) can allow it to weather the sector storm and return to growth before the stock's valuation premium completely erodes. The resolution of this tension—specifically, the next few quarters of revenue and margin trends—will determine if this is a value trap or a turnaround opportunity.
Bullish
- Strong Balance Sheet & Liquidity: The company's current ratio of 3.46 and debt-to-equity ratio of 0.23 indicate a fortress-like financial position with ample liquidity and minimal leverage. This provides significant resilience to navigate the current industry downturn and flexibility for strategic investments or share buybacks.
- Healthy Free Cash Flow Generation: Despite earnings pressure, the company generated $223.02 million in trailing twelve-month free cash flow. This strong cash generation supports the dividend, funds operations internally, and reduces reliance on external capital, a key advantage in a high-interest rate environment.
- Analyst Bullish Sentiment Amid Decline: Major institutions like Citigroup, UBS, and TD Cowen maintain 'Buy' ratings despite the stock's 21.65% six-month decline, suggesting they view the sell-off as an overreaction. The forward EPS consensus of $2.66 implies a forward P/E of 23.35x, pricing in a significant earnings recovery.
- Oversold Technical Condition: The stock trades at $48.21, only 17.4% above its 52-week low of $43.2, following a severe 17.70% one-month decline. This deep oversold condition, coupled with a beta of 1.4, suggests the potential for a sharp technical rebound if any positive catalyst emerges.
Bearish
- Stalled Revenue & Negative YoY Growth: Q2 2026 revenue of $295.88 million represents a 0.39% year-over-year decline, indicating top-line stagnation. The core consumables segment generated $235.44 million, showing the recurring revenue model is under direct pressure from reduced biotech R&D spending.
- Severe Profitability & Margin Compression: Gross margin has compressed to 64.65% in Q2 2026 from 67.83% in Q3 2025, indicating pricing pressure or an unfavorable product mix. The trailing P/E of 110.41x, while distorted by depressed earnings, highlights the extreme earnings volatility and recent profitability challenges.
- Extreme Relative Underperformance: The stock has underperformed the S&P 500 by 22.54 percentage points over the past month and 34.79 points over six months. This severe relative weakness signals a fundamental disconnect with the broader market rally and a lack of investor confidence in near-term prospects.
- Valuation in Transition; High Trailing Multiples: The trailing P/E of 110.41x and Price/Sales of 6.64x are elevated and reflect depressed trailing earnings. The investment thesis is entirely dependent on the forward P/E of 23.35x materializing, which requires a successful earnings rebound that is not yet evident in recent results.
TECH Technical Analysis
The stock is in a pronounced downtrend, having declined 21.65% over the past six months and currently trading at $48.21, which is just 17.4% above its 52-week low of $43.2. This positioning near the bottom of its annual range suggests the stock is deeply oversold, potentially presenting a value opportunity, though it also risks being a 'falling knife' amid persistent negative momentum. Recent momentum is decisively negative, with the stock down 17.70% over the past month and 16.19% over the past three months, significantly underperforming the S&P 500, which gained 4.84% and 8.15% over the same periods, respectively, indicating severe relative weakness and a lack of near-term catalysts. Key technical support is firmly established at the 52-week low of $43.2, while resistance lies at the 52-week high of $72.16; a breakdown below support could trigger further selling, while a sustained move above the recent downtrend would require a fundamental catalyst. The stock's beta of 1.405 confirms it is approximately 40% more volatile than the broader market, which amplifies both downside risk and potential upside during a recovery, necessitating careful risk management for investors.
Beta
1.41
1.41x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$43-$72
Price range past year
Annual Return
+6.9%
Cumulative gain past year
| Period | TECH Return | S&P 500 |
|---|---|---|
| 1m | -0.5% | +6.3% |
| 3m | -12.4% | +10.3% |
| 6m | -19.9% | +10.7% |
| 1y | +6.9% | +28.2% |
| ytd | -13.4% | +10.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TECH Fundamental Analysis
Revenue growth has stalled, with the most recent quarterly revenue of $295.88 million representing a slight 0.39% year-over-year decline, and the multi-quarter trend shows volatility, including a significant drop in the prior quarter (Q4 2025) to $316.96 million. Segment data indicates the core 'Consumables' business generated $235.44 million, while 'Instruments' contributed $29.61 million, suggesting the company's recurring revenue model is under pressure, potentially from reduced biotech R&D spending. The company remains profitable on a quarterly basis, posting net income of $38.01 million and a gross margin of 64.65% in Q2 2026, but margins have compressed from the 67.83% gross margin reported in Q3 2025, indicating pricing pressure or product mix shifts. The trajectory shows a recovery from a net loss of -$17.68 million in Q4 2025, yet profitability levels remain below the peaks seen in earlier quarters, such as the $49.06 million net income in Q3 2024. The balance sheet is healthy with a strong current ratio of 3.46 and a low debt-to-equity ratio of 0.23, indicating ample liquidity and low financial leverage. The company generates solid free cash flow, with a trailing twelve-month figure of $223.02 million, providing internal funding for operations and potential investments, though the Return on Equity of 3.83% is currently subdued, reflecting the recent earnings pressure.
Quarterly Revenue
$295877000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$223020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TECH Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is extremely elevated at 110.41x, while the forward PE is a more reasonable 23.35x; this wide gap implies the market expects a significant earnings recovery, pricing in the consensus EPS estimate of $2.66 for the forward period. Compared to sector averages, the stock's trailing PS ratio of 6.64x and forward PE of 23.35x are not provided with direct industry benchmarks in the data, but the high trailing PE suggests a premium that is contingent on the anticipated earnings rebound materializing. Historically, the stock's own valuation has compressed significantly; its current trailing PE of 110.41x is above the historical range seen in recent quarters (e.g., 56.62x in Q1 2026, 60.28x in Q2 2026), but this is largely an artifact of depressed trailing earnings rather than market optimism, placing it in a state of valuation transition pending future results.
PE
110.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -113x~293x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on earnings volatility and margin sustainability. The company's trailing P/E of 110.41x, though an artifact of depressed earnings, underscores extreme profit instability, with net income swinging from a $49.06 million profit in Q3 2024 to a $17.68 million loss in Q4 2025. Gross margin compression from 67.83% to 64.65% over recent quarters indicates pricing power erosion. Revenue concentration is a key risk, with ~75% of sales tied to the protein sciences segment, making the company highly vulnerable to a prolonged downturn in biotech funding and capital expenditure.
Market & Competitive Risks are pronounced given the stock's premium valuation and sector sensitivity. The forward P/E of 23.35x, while more reasonable, still prices in a robust earnings recovery (consensus EPS $2.66) that may not materialize if sector headwinds persist. The stock's beta of 1.405 means it is 40% more volatile than the market, amplifying downside during risk-off periods. Competitive disruption and continued pressure on biotech R&D budgets pose external threats, as evidenced by the stock's severe underperformance (-34.79 pp vs. S&P 500 over 6 months) despite a strong broader market.
Worst-Case Scenario involves a failure of the anticipated earnings rebound coupled with a deepening sector recession. This could trigger a breakdown below key technical support at the 52-week low of $43.20, leading to a re-rating to a deeper discount. Given the stock's 52-week high of $72.16 and a recent max drawdown of -39.33%, a realistic downside scenario could see the stock retesting and breaking below its low, leading to a further 15-20% decline from the current $48.21. This implies a potential loss of -35% to -40% from the current price, aligning with a move toward the $38-$41 range if sentiment deteriorates further and forward estimates are cut.
FAQ
The key risks are, in order of severity: 1) Sector & Fundamental Risk: Continued pressure on biotech R&D spending, leading to further revenue declines and margin erosion, as seen in the recent -0.39% YoY revenue growth. 2) Valuation Risk: The forward P/E of 23.35x could compress sharply if the anticipated EPS recovery fails to materialize, leading to significant multiple contraction. 3) Technical & Sentiment Risk: The stock is in a pronounced downtrend and a breakdown below the $43.20 support could trigger accelerated selling, given its high beta of 1.405. 4) Concentration Risk: Approximately 75% of revenue comes from the protein sciences segment, creating overexposure to a single, currently challenged end-market.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $50 and $60, as the company stabilizes operations in a tough environment. The Bull Case (25% probability) projects a rally to $65-$72 on a successful return to growth and margin improvement. The Bear Case (20% probability) warns of a drop to $40-$45 if fundamentals worsen and support breaks. The Base Case is most likely, predicated on the assumption that the challenging biotech funding environment persists but does not catastrophically worsen, allowing TECH to tread water while investors await a clearer recovery signal.
TECH's valuation is in a state of transition and is challenging to categorize simply. Based on trailing earnings, it appears extremely overvalued with a P/E of 110.41x, but this is misleading due to recent earnings volatility. The forward P/E of 23.35x, based on a $2.66 EPS estimate, is more meaningful but still implies the market is paying a premium for a significant earnings recovery that has not yet begun. Compared to its own depressed price near 52-week lows, it may seem undervalued technically. Overall, the stock is likely fairly valued to slightly overvalued relative to its current fundamentals, as the forward multiple already discounts a successful turnaround.
TECH is a speculative buy only for investors with a high risk tolerance and a long-term view. The stock is deeply oversold (down 21.65% in six months) and has a fortress balance sheet (debt-to-equity 0.23), which provides a margin of safety. However, it is not a good buy for conservative investors, as it requires a belief that the company can return to growth to justify its forward P/E of 23.35x. The current negative revenue growth and margin compression make it a 'show me' story. It could be a good buy for contrarians if they are willing to wait for a sector recovery, but timing the entry is difficult given the lack of near-term catalysts.
TECH is unsuitable for short-term trading due to its high volatility (beta 1.4), negative momentum, and lack of immediate catalysts. It is best considered a long-term, cyclical recovery play for investors with a minimum 2-3 year horizon. This timeframe allows for the potential resolution of current sector headwinds and for the company's financial recovery narrative to play out. The modest dividend yield of 0.62% does not provide sufficient income to justify a hold for income investors. Therefore, it is primarily suited for patient capital betting on a mean reversion in both the sector's fortunes and the company's operational performance.